📰 ReutersReutersCodex · 实盘不做把握 4/10不做原因:证据不足
北京时间·🕒 发布 00:58:54时区推断·⟳ 抓取 01:02:24·⚡ 决策 08-26 01:03:35 +1m11s·62.8 天前
Bristol Myers终止与Cellares的Breyanzi商业化生产扩产合作
当前事实不足以把BMY定为明确做多或做空；直接受损方Cellares不可交易，且指定行情、案例库和先例工具未暴露，不能生成满足契约的ENTER订单。
📄 原文Reuters↗ 原文
Bristol Myers Squibb (BMY.N) has ended its partnership with cell therapy startup Cellares to expand the manufacturing o…
不做 Bristol Myers Squibb（BMY.US）
终止Cellares合作对BMY净影响混合，未披露Breyanzi供应或指引受损；直接受损方未上市，且无真实行情与event_study支持可执行交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Reuters报道确认BMY终止Cellares为Breyanzi扩产的合作，说明Cellares平台商业化放大受挫，对Cellares是实质利空；但对BMY更像供应链去风险和制造路径调整，未披露Breyanzi供应中断、销售指引下修或替代产能缺口。Breyanzi 2025年约13.6亿美元销售，占BMY 2025年482亿美元收入约2.8%；3.8亿美元合作额是最高协议额且非BMY收入损失。缺少可交易受损标的和可验证正期望，不做。
消息传播链
- 本地信号库已抓到Reuters原文《Telecoms operator MTN eyes banking licences as it pushes deeper into lending》，发布时间早于当前社媒/聚合转述，用作本次催化首发锚点。
- 2026-08-25首发Endpoints News非一手Reuters正文称Endpoints News在当日更早率先报道BMS终止Cellares合作；未在本轮命中可直接访问原文链接。
- Reuters引述Bristol Myers发言人确认终止与Cellares的Breyanzi制造扩产合作，发布时间接近抓取时点。
- FiercePharma报道Cellares CEO披露失去大型药企客户并将裁员，但当时未点名BMS。
- BioPharma Dive报道Cellares因未具名大型合作方终止合同而裁员100人，说明消息在BMY被点名前已有行业传播。
关键理由
- BMY终止合作反映对Breyanzi商业规模制造质量和可靠性的控制，未等同于药品需求或销售受损。
- 量级上，Breyanzi 2025年销售约13.6亿美元，占BMY 2025年总收入约2.8%；本事件未披露供应中断或收入指引下修。
- Cellares作为未上市合作方承受直接冲击，上市市场缺少纯粹、已坐实的直接受损载体。
主要风险
- 若后续BMY披露Breyanzi产能不足、交付延迟或销售指引下修，BMY事件方向会转为更明确负面。
- 本环境缺少指定stock_tools，未能完成强制去重、真实报价和event_study，订单层面必须保守为AVOID。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-25 · 影响 weakens
未在可访问结果中看到BMY披露Breyanzi供应中断或销售指引下修；Reuters称决定仅适用于Breyanzi及其已获批制造流程。
检索:Bristol Myers Breyanzi Cellares termination supply disruption guidance 原文 ↗ - 做多前查反向 · 来源 web · 影响 weakens
Breyanzi约13.6亿至14亿美元销售相对BMS 482亿美元总收入占比约2.8%，且本事件不是新增收入或获批催化。
检索:Bristol Myers Breyanzi sales 2025 total revenue 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使本次只保留事实判断，不生成ENTER订单。
方向:未完成合格event_study，不能用历史先例支持交易方向。
涨幅量级:缺少同市场同相位的已量化先例，不能校准tp/sl。
形态:未能确认类似大药企终止未上市CDMO制造合作对大药企股价存在稳定短线方向。
原文全文
展开原文 · 1,641 字
Bristol Myers Squibb (BMY.N) has ended its partnership with cell therapy startup Cellares to expand the manufacturing of its personalized blood cancer therapy, a company spokesperson told Reuters on Tuesday.
Bristol Myers determined that Cellares' cell therapy manufacturing platform, Cell Shuttle, could not meet the requirements to make its CAR-T therapy, Breyanzi, at commercial scale, the spokesperson said. Cellares did not immediately respond to a Reuters request for comment.
The development underscores the challenges of manufacturing CAR-T therapies, a personalized form of cancer treatment that has transformed care for some blood cancer patients but remains difficult and expensive to produce.
Breyanzi, first approved by the U.S. FDA in 2021, is used to treat lymphoma and other blood cancers. It generated $1.36 billion in sales in 2025.
Endpoints News first reported the development earlier in the day.
Cellares CEO Fabian Gerlinghaus had disclosed the loss of a "large pharmaceutical customer" in a LinkedIn post over the weekend, adding that this will force the company to "resize" its workforce.
The start up did not immediately respond to a request for comment on the layoffs.
The companies signed a deal in 2024 worth up to $380 million under which Bristol Myers reserved manufacturing capacity across the U.S., the European Union and Japan for CAR-T therapies.
Bristol Myers' decision only applies to Breyanzi and its approved manufacturing process.
CAR-T therapies work by removing a patient's immune cells, reprogramming them in a lab to fight cancer, and infusing them back into the body.
Bristol Myers determined that Cellares' cell therapy manufacturing platform, Cell Shuttle, could not meet the requirements to make its CAR-T therapy, Breyanzi, at commercial scale, the spokesperson said. Cellares did not immediately respond to a Reuters request for comment.
The development underscores the challenges of manufacturing CAR-T therapies, a personalized form of cancer treatment that has transformed care for some blood cancer patients but remains difficult and expensive to produce.
Breyanzi, first approved by the U.S. FDA in 2021, is used to treat lymphoma and other blood cancers. It generated $1.36 billion in sales in 2025.
Endpoints News first reported the development earlier in the day.
Cellares CEO Fabian Gerlinghaus had disclosed the loss of a "large pharmaceutical customer" in a LinkedIn post over the weekend, adding that this will force the company to "resize" its workforce.
The start up did not immediately respond to a request for comment on the layoffs.
The companies signed a deal in 2024 worth up to $380 million under which Bristol Myers reserved manufacturing capacity across the U.S., the European Union and Japan for CAR-T therapies.
Bristol Myers' decision only applies to Breyanzi and its approved manufacturing process.
CAR-T therapies work by removing a patient's immune cells, reprogramming them in a lab to fight cancer, and infusing them back into the body.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。